|
| |
| |
|
 |
Inpharmatica announces
ISO 9001 Certification for its ADME business |
Award confirms the high
customer satisfaction that is driving continued growth in Admensa sales
London 15 May 2006 - Inpharmatica Ltd., the selective drug discovery
company, today announces the award of ISO 9001:2000 quality certification for
its comprehensive ADME (absorption, distribution, metabolism and excretion)
business, Admensa(TM). The internationally accepted ISO 9001 Certification
recognises Inpharmatica's commitment to an exceptional quality of service and
customer care within its Admensa division.
The high level of customer care and service is bringing Inpharmatica an
expanding list of international companies who have chosen to work with
Inpharmatica to address their ADME needs. More than 40 customers have signed up
to use Admensa, including recent additions Ark Therapeutics Group PLC, KuDOS
Pharmaceuticals Limited, iQur Limited and Canbex Therapeutics Limited, a spin
out from UCL's Wolfson Institute.
Admensa offers a unique combination of ADME optimisation expertise, proprietary
in silico tools, laboratory services and consulting, to enable early selection
of compounds with an optimal balance of drug like properties. The combined
approach provides expert assessments and decision support to improve timelines
and success rates from lead discovery through to candidate selection.
A module of Admensa, Admensa Interactive(TM), Inpharmatica's in silico
optimisation platform for drug discovery scientists, has recently been enhanced
to offer improved QSAR ADME models, P450 metabolism models and unique compound
prioritisation and selection methods within an intuitive, interactive design
environment.
Admensa itself is an integral component of Inpharmatica's gene-to-candidate
technology platform which integrates biology- and chemistry-based drug discovery
activities. The complete platform optimises target selection based on
druggability, and enables rapid identification of hits and selection of high
quality leads and pre-clinical candidates, which are prioritised on the basis of
good drug-like characteristics and clinical indication.
Commenting on the announcement, John Lisle, Inpharmatica's CEO, said: "This ISO
9001 certification means that Inpharmatica's customers can be even more
confident that they will receive an excellent product and an excellent level of
service and customer care. We have already seen high levels of customer
satisfaction and the company is enjoying the extra sales that this brings."
About Inpharmatica :
www.inpharmatica.com/admensa.htm
Founded in 1998, Inpharmatica uses predictive informatics in genomics, medicinal
chemistry and ADME to improve the speed and productivity of drug discovery. The
company employs around 90 professionals at its UK locations in London and
Cambridge, with business development in North America and Japan. Inpharmatica's
unique proprietary technologies and skills are utilised in major discovery
laboratories worldwide including Serono, Pfizer, GSK, Novartis, Sanofi-Aventis,
P&G Pharmaceuticals, and Daiichi.
Inpharmatica is unique in offering discovery technologies and services which
span the full breadth of research from gene through to candidate selection: the
core elements are fully integrated, enabling customers to access the full
end-to-end technologies, or individual components and services as required.
For more information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Heidi Thompson
Tel: +44 1273 675100
allo@ala.com /
heidi@ala.com
Inpharmatica Ltd
John Lisle, Chief Executive Officer
Tel: +44 (0)20 7074 4600
Dr Vimal Mehta, Sr. VP Business Development
Tel: +1 203 453 6525
| |
|
